Diversified Trust Co raised its position in Amgen Inc. (NASDAQ:AMGN) by 12.5% in the 3rd quarter, Holdings Channel reports. The fund owned 20,159 shares of the medical research company’s stock after acquiring an additional 2,246 shares during the period. Diversified Trust Co’s holdings in Amgen were worth $5,124,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently added to or reduced their stakes in AMGN. Price Wealth LLC lifted its stake in shares of Amgen by 42.9% in the 2nd quarter. Price Wealth LLC now owns 140 shares of the medical research company’s stock worth $33,000 after acquiring an additional 42 shares during the period. Lake Point Wealth Management lifted its stake in shares of Amgen by 1,590.0% in the 1st quarter. Lake Point Wealth Management now owns 169 shares of the medical research company’s stock worth $34,000 after acquiring an additional 159 shares during the period. Campbell Wealth Management acquired a new stake in shares of Amgen in the 2nd quarter worth $51,000. Demars Financial Group LLC acquired a new stake in shares of Amgen in the 2nd quarter worth $53,000. Finally, 1776 Wealth LLC acquired a new stake in shares of Amgen in the 2nd quarter worth $59,000. Institutional investors own 75.23% of the company’s stock.
In related news, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $241.02, for a total value of $241,020.00. Also, Director R Sanders Williams sold 250 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $242.95, for a total transaction of $60,737.50. Following the completion of the sale, the director now owns 5,159 shares of the company’s stock, valued at $1,253,379.05. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,250 shares of company stock valued at $561,548. Insiders own 0.36% of the company’s stock.
Several analysts have recently commented on AMGN shares. Cantor Fitzgerald raised their target price on shares of Amgen from $263.00 to $279.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. SVB Leerink raised their price objective on shares of Amgen from $253.00 to $261.00 and gave the company a “market perform” rating in a research note on Wednesday, July 29th. Credit Suisse Group reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, July 29th. Raymond James reiterated a “market perform” rating on shares of Amgen in a research note on Tuesday, October 6th. Finally, Barclays raised their price objective on shares of Amgen from $245.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 29th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and fifteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $255.08.
Shares of NASDAQ AMGN opened at $235.72 on Friday. The company has a market cap of $138.06 billion, a PE ratio of 19.26, a price-to-earnings-growth ratio of 2.11 and a beta of 0.81. Amgen Inc. has a 12 month low of $177.05 and a 12 month high of $264.97. The company has a debt-to-equity ratio of 3.20, a current ratio of 2.18 and a quick ratio of 1.81. The company has a 50-day simple moving average of $246.43 and a 200-day simple moving average of $237.88.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.81 by $0.44. The business had revenue of $6.21 billion during the quarter, compared to the consensus estimate of $6.19 billion. Amgen had a net margin of 30.04% and a return on equity of 91.98%. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.97 earnings per share. On average, analysts anticipate that Amgen Inc. will post 15.66 EPS for the current year.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.